INTRODUCTION
Prion diseases, or transmissible spongiform encephalopathies, are a group of central nervous system neurodegenerative disorders that affect both humans and animals. These diseases, which include Creutzfeldt-Jakob disease (CJD) of humans, bovine spongiform encephalopathy (BSE) of cattle and scrapie of sheep, are believed to comprise a common pathogenic mechanism that involves the conversion of a normal cellular prionrelated protein (PrP c ) into a form that is infectious and partially protease resistant, termed PrP Sc (the abnormal disease-specific conformation of PrP) [1, 2] . The conversion of PrP c into PrP Sc is considered to involve a conformational change from the predominantly α-helical form of PrP c to the predominantly β-sheet structure of PrP Sc [3] [4] [5] [6] . At present, the only established diseasespecific marker of prion diseases is the accumulation of PrP Sc in nervous tissue, and in some cases peripheral lymphoid tissue, of affected individuals [7] [8] [9] [10] [11] [12] . The relationship between PrP Sc , the identity of the infectious agent and the neurotoxic molecule responsible for pathology seen in these diseases remains to be clarified [13] . It is important therefore to generate reagents that identify PrP Sc and other possible pathogenic forms of the PrP molecule that may act as intermediates in the disease process. Such reagents will be essential in the elucidation of the mechanism of disease pathogenesis and in the diagnosis of infected individuals, particularly during preclinical prion disease.
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A "$' R "&% R "(" (' ARR ') of recombinant ovine PrP c . FACS analysis of lymphoid cells using these monoclonal antibodies showed that wild-type non-activated mouse lymphocytes expressed little, if any, PrP c . These monoclonal antibodies were shown to react with the unglycosylated and monoglycosylated forms of PrP Sc (abnormal disease-specific conformation of PrP) in prion-infected tissue samples from all of the different species tested by Western blot. In addition, this analysis allowed one to make a distinction between bovine spongiform encephalopathy (' BSE ') and scrapie PrP Sc isolates from experimentally infected sheep on the basis of their different electrophoretic mobilities.
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velopment of prion diseases [14] , the normal function of PrP c remains an enigma. Several lines of evidence have indicated that the trace element copper may influence the biology of PrP c . It has been shown that the N-terminal octapeptide repeat region of PrP c binds copper ions with high affinity [15] [16] [17] [18] [19] [20] . This interaction is dependent upon pH and induces a conformational change in the normally unstructured N-terminal region of PrP [17, 21] . The binding of copper to PrP c rapidly and reversibly stimulates the endocytosis of this protein from the cell surface, indicative of a role for PrP c in the cellular transport of copper [22] . A disturbance in PrP-mediated copper metabolism or transport is implicated as a contributing factor in prion disease through the interaction of this metal ion with PrP Sc . Copper facilitates the restoration of protease resistance and infectivity associated with guanidinedenatured PrP Sc [23] . Copper has also been reported [24] to convert PrP c into a protease resistant form that is distinct from PrP Sc . In addition, the cleavage pattern of human CJD PrP Sc is affected by its copper ion occupancy [25] . Collectively, these observations strongly suggest that the molecular nature of both PrP c and PrP Sc is likely to be influenced by copper and possibly other related metal ions.
The majority of existing monoclonal antibodies specific for PrP have been generated through immunization with either recombinant protein refolded in the absence of metal ions or short synthetic peptides. It is clear that a full understanding of the biology of PrP and the pathogenesis of prion diseases will require a diverse panel of PrP-specific reagents. These may allow the identification of possible intermediates involved in the conversion of PrP c into PrP Sc . In the present study, we have immunized PrP −/− mice with murine recombinant PrP c that has been refolded in the presence of copper to obtain a panel of monoclonal antibodies specific for PrP. These monoclonal antibodies react with PrP from a variety of mammals, including bovine, ovine and murine species forms. They are capable of detecting PrP c on the surface of cells measured by FACS, and can identify PrP Sc by Western blot. In the present study, we report our initial characterization of these monoclonal antibodies in terms of their reactivity with normal and pathogenic forms of PrP.
MATERIALS AND METHODS

Mice
PrP −/− [26] and tga20 mice [27] were obtained from Professor Charles Weissmann (MRC Prion Unit\Neurogenetics, Imperial College School of Medicine, London, U.K.). 129SviC57BL\6 F1 were bred in house from 129Sv and C57BL\6 wild-type mice purchased from Harlan UK (Bicester, Oxon., U.K.). All regulated procedures involving experimental animals were carried out under a project and personal licence authority issued in accordance with The Animals (Scientific Procedures) Act 1986.
Purification of recombinant PrP c and truncated PrP peptides
Recombinant PrP c was purified from BL21(DE3)pLysS bacteria transformed with the prokaryotic expression vector pET-23b, which contained the open reading frame coding sequence of mature murine PrP c , ovine PrP c-VRQ (where VRQ represents the disease-susceptible allelic form V "$' R "&% Q "(" ; single-letter aminoacid notation has been used) or ovine PrP c-ARR (where ARR represents the disease-resistant allelic form A "$' R "&% R "(" ). For truncated peptides of murine PrP c , BL21(DE3)pLysS cells were transformed with pET-23b that contained DNA encoding amino acids 23-90, 91-159 or 160-231 of the full-length protein (PrP23-90, PrP91-159 and PrP160-231 respectively). Transformed bacteria were grown at 37 mC in Luria-Bertani broth supplemented with 100 µg\ml ampicillin and induced with 1 mM isopropyl β--thiogalactoside. Bacteria were harvested by centrifugation at 4000 g for 15 min at 4 mC, resuspended in 20 mM Tris\HCl, 8 M urea and 20 mM imidazole (pH 7.5) and lysed by sonication. The soluble fraction was applied to a nickelSepharose column and PrP c protein was eluted off the column with 20 mM Tris\HCl, 8 M urea and 500 mM imidazole (pH 7.5). Full-length murine PrP c was refolded by rapid dilution into 20 mM Tris\HCl (pH 6.5) in the absence or presence of copper or manganese [28] to a final approximate concentration of 50 ng\µl. Residual traces of urea and imidazole were removed by dialysis in PBS. The samples were snap-frozen in liquid nitrogen and stored at k70 mC.
Generation of monoclonal antibodies
Monoclonal antibodies were prepared by conventional hybridoma technology [29] . Briefly, 6-week-old PrP −/− mice were immunized by subcutaneous injection with 50 µg of copperrefolded recombinant PrP emulsified in complete Freund's adjuvant and boosted twice at monthly intervals with a similar amount of PrP in incomplete Freund's adjuvant. Mice were finally injected intravenously with antigen in PBS 3 days prior to the fusion. Spleens were removed and single cell suspensions were fused to the NS0 cell line and selected in hypoxanthine\ aminopterin\thymidine (' HAT ') medium. Supernatants were screened by ELISA using murine and ovine recombinant PrP as antigens, and positive cell lines were cloned by limiting dilution. Antibody was purified from hybridoma tissue culture supernatant by affinity chromatography on Protein G columns. 
Isolation of spleen mononuclear cells for immunofluorescence staining
Spleens were isolated from mice, placed in FACS buffer [PBS containing 1 % (v\v) heat-inactivated fetal-calf serum and 0.1 % sodium azide] and processed through a nylon cell strainer (40 µm pore size). Single cell suspensions were layered on to NycoPrep TM Animal (density 1.077 g\ml ; osmolarity 265 mOsm) and centrifuged at 600 g for 15 min at 21 mC. Mononuclear cells were recovered from the density medium interface and washed three times in FACS buffer prior to immunofluorescence staining. Cell-surface phenotype was assessed using samples of 1i10' cells incubated with 2.5 µg of biotinylated monoclonal antibody for 20 min at 4 mC, followed by 0.25 µg of streptavidinphycoerythrin for 20 min at 4 mC. Cells were washed three times with FACS buffer following each treatment. FACS analysis was performed using a FACSCalibur2 (Becton Dickinson, Mount View, CA, U.S.A.). Cells (10 000 per sample) were analysed, with dead cells excluded on the basis of forward-and side-light scatter.
Western-blot analysis for recombinant PrP and truncated peptides
For Western-blot analysis of recombinant PrP, proteins were subjected to SDS\PAGE under reducing conditions and were subsequently transferred on to nitrocellulose membranes by semi-dry blotting. Membranes were blocked with Tris-buffered saline [TBS ; 10 mM Tris\HCl (pH 7.8) and 100 mM NaCl] and 0.05 % Tween 20 (TBS-T) containing 5 % (w\v) non-fat milk and subsequently incubated in 1 % (w\v) non-fat milk in TBS-T with rabbit polyclonal anti-PrP serum XN [30] or mouse polyclonal or monoclonal antibodies for 60 min. These were followed by either biotin-conjugated goat anti-(rabbit IgG) (Sigma) or biotin-conjugated goat anti-(mouse IgG) (Sigma) and finally extravidin-horseradish peroxidase (Sigma). All detection antibodies were diluted 1 : 1000 in 1 % (w\v) non-fat milk in TBS-T. PrP bands were detected by enhanced chemiluminescence (ECL ; Sigma).
Extraction of PrP Sc and detection by Western blot
PrP Sc was extracted from various sources, including the murine neuroblastoma cell line N2a58\22L, which are persistently infected with the 22L scrapie strain, and tissues from prioninfected animals. The animal tissues were from cases of natural scrapie in sheep or BSE in cattle identified by the French surveillance laboratories. Tissues from experimental BSE of sheep [31] or mice inoculated with the C506M3 prion strain [32] were obtained as reported previously [31, 32] . PrP Sc was extracted from N2a58\22L cells in a 25 cm# flask by lysis of the cell sheet in 1 ml of Triton X-100\deoxycholic acid lysis buffer [150 mM NaCl, 0.5 % Triton X-100, 0.5 % deoxycholic acid and 50 mM Tris\HCl (pH 7.5)] on ice for 15 min. The supernatant was collected and the total protein concentration was adjusted with lysis buffer to 1 mg\ml. The samples were digested with 20 µg\ml of proteinase K (Roche, Lewes, East Sussex, U.K.) at 37 mC for 30 min, and the digestion was stopped by the addition of 5 mM PMSF for 5 min on ice. The samples were centrifuged at 20 000 g for 45 min at 4 mC and the pellet was resuspended in 30 µl of denaturing buffer [4 % (w\v) SDS, 2 % (v\v) 2-mercaptoethanol, 192 mM glycine, 25 mM Tris\HCl (pH 7.5) and 5 % (w\v) sucrose] and heated for 5 min at 100 mC before analysis by SDS\PAGE. For the extraction of PrP Sc from tissues, samples were homogenized (10 %, w\v) in a 5 % (w\v) glucose solution.
Homogenates were forced through a 0.4 mm diameter needle before treatment at 37 mC for 60 min with 10 µg of proteinase K\100 mg of tissue. After the addition of N-lauroylsarkosyl to produce a final concentration of 10 % (w\v), samples were incubated for 15 min at 21 mC and then centrifuged at 465 000 g for 2 h on a 10 % (w\v) sucrose cushion (TL 100 ultracentrifuge ; Beckman, High Wycombe, Bucks., U.K.). The pellets were resuspended in 100 µl of denaturing buffer, heated for 5 min at 100 mC and re-centrifuged at 12 000 g for 15 min at 21 mC. Finally, the pellet was discarded and the supernatant analysed by SDS\PAGE. PrP samples were separated on 15 % (w\v) polyacrylamide gels and the proteins were transferred on to nitrocellulose membranes (Bio-Rad Laboratories, Hemel Hempstead, Herts., U.K.) in 25 mM Tris\192 mM glycine\10 % (v\v) isopropanol buffer at 400 mA constant for 60 min. For immunoblotting, the membranes were blocked with 5 % (w\v) non-fat milk in PBS containing 0.1 % Tween 20 (PBS-T20) and subsequently incubated for 60 min at 21 mC with the rabbit polyclonal anti-PrP serum XN or RB1 [33] , or individual anti-PrP monoclonal antibodies. The membranes were subsequently washed twice in PBS-T20 and incubated in peroxidase conjugated anti-(rabbit Ig) or anti-(mouse IgG) antibody (1 : 2500 dilution ; Southern Biotechnology Associates, Birmingham, AL, U.S.A.) in PBS-T20 for 30 min at 21 mC. Blots were finally washed three times in PBS-T20 and once in PBS before the bound antibodies were visualized on film (Biomax Light ; Kodak) using ECL [ECL2 (Amersham Biosciences) or Super Signal Ultra (Pierce)].
Deglycosylation of PrP Sc
Pellets obtained after proteinase K treatment and ultracentrifugation of PrP Sc -infected brain homogenates were denatured by heat treatment at 100 mC for 10 min in 50 µl of 0.5 % SDS in distilled water. After addition of 200 µl of 0.5 % Triton X-100 in 50 mM Tris\HCl (pH 8.0) containing 5 mM PMSF, the samples were treated with peptide N-glycosidase F (Roche) (1 unit\sample) and incubated at 37 mC overnight. Proteins were subsequently precipitated in ethanol and resuspended in 50 µl of denaturing buffer before analysis by SDS\PAGE.
RESULTS
Characterization of monoclonal antibodies reactive with PrP
We have generated a panel of anti-PrP monoclonal antibodies by immunization of PrP −/− mice with copper-refolded murine recombinant PrP c . Positive hybridoma tissue culture supernatants were initially identified by ELISA using murine or ovine recombinant PrP c as substrate. Hybridoma cells were subsequently cloned by limiting dilution and, from a total of 30 positive hybridomas, eight clones (numbered 241, 242, 244, 245, 246, 248, 249 and 251) were used for further investigation and the data reported in the present study. Monoclonal antibodies were purified from tissue culture supernatant by affinity chromatography on Protein G columns. Preliminary characterization of the monoclonal antibodies by SDS\PAGE showed the presence of light-and heavy-chain protein bands at approx. 55 kDa and 25 kDa respectively, indicative of an IgG antibody (results not shown). The purity of the Protein G-purified monoclonal antibodies was estimated to be 99 % as judged by SDS\PAGE and Coomassie Blue staining. The monoclonal antibodies were all of the IgG " isotype except for 246, which was IgG $ .
Reactivity of monoclonal antibodies with metal-ion-refolded PrP c
PrP c has been shown to bind copper within its N-terminal octapeptide repeat region and, in addition, between these motifs and the C-terminal globular domain [15] [16] [17] [18] [19] [20] . The binding of copper to the N-terminal octapeptide repeat region induces a more ordered structure to this part of the molecule that is normally highly flexible. It has also been reported [28] that manganese may substitute for the binding of copper to PrP, although the conformational changes that result are not established. We investigated whether the monoclonal antibodies raised to copper-refolded PrP c did indeed show a preference for this form of prion protein. Initially, representative monoclonal antibodies were tested by Western-blot analysis for their reactivity with copper-or manganese-refolded murine PrP c or PrP c refolded in the absence of any metal ion. Figure 1 shows that the monoclonal antibodies 249 and 251 both reacted with all three forms of PrP c and in each case a single band of approx. 25 kDa, which corresponds to the molecular mass of murine recombinant PrP, was detected. As a control, the rabbit polyclonal anti-PrP serum XN [30] was shown to react with a protein band of the same molecular mass for all three forms of PrP c as for the monoclonal antibodies. The reactivity of the monoclonal antibodies with metal-ionrefolded PrP c was subsequently investigated by ELISA, where the conformation of the different forms of PrP c may resemble the native shape of the molecule compared with the presumably denatured form that occurs in SDS\PAGE. Figure 2 shows that the monoclonal antibodies could be divided into two groups. The first, comprising 241, 244 and 248, which showed equal reactivity with all three forms of PrP, and a second group, comprising 242, 245, 249 and 251, which showed stronger reactivity with copper-refolded PrP c compared with PrP c with no metal ion. Within this second set there was differential reactivity for manganese-refolded PrP c exemplified by 245 and 251. Antibody 246 was not included as it only showed low reactivity (results not shown). The rabbit polyclonal anti-PrP serum XN showed the same reactivity profile with all three forms of PrP c . These data suggest that the metal-ion occupancy of PrP c does influence the binding of monoclonal antibodies to this protein. Figure 3 shows the reactivity of the panel of monoclonal antibodies with either murine or ovine recombinant PrP c , refolded in the absence of any metal ion, measured by ELISA. Predictably, because of the high degree of amino acid sequence conservation between different species forms of PrP, all of the monoclonal antibodies reacted to some extent with either murine or ovine recombinant PrP c . However, there was some variation in their apparent affinity for the different species forms of PrP c . For example, monoclonal antibody 248 reacted well with ovine PrP c , but bound weakly to murine PrP c . A further difference between some of the monoclonal antibodies was seen with their reactivity with different allelic forms of ovine recombinant PrP c . Expression in sheep of the VRQ and ARR allelic forms of ovine PrP c is associated with high and low risk of scrapie disease respectively [34, 35] . These variations in amino acid residues are located at positions 136, 154 and 171 of the mature ovine PrP c protein, which may represent regions of the PrP molecule that are affected by metal-ion binding. Some of the monoclonal antibodies appeared to differ in their affinity for the different allelic forms of ovine PrP c . For example, monoclonal antibody 245 reacted well with ovine PrP c−VRQ , but bound weakly to ovine PrP c−ARR .
Cross-reactivity of anti-PrP monoclonal antibodies with different species forms of recombinant PrP c
Regional epitope mapping of anti-PrP monoclonal antibodies with truncated peptides of PrP
Truncated forms of murine PrP c corresponding to amino acids 23-89, 90-159 and 160-231 were expressed from a prokaryotic expression vector in order to determine which region of the PrP molecule the monoclonal antibodies recognized. Each PrP peptide contained a C-terminal His ' tag, which allowed its purification by affinity chromatography on a nickel-ion column. These purified truncated forms of PrP c were subsequently used to localize the binding region of the different monoclonal antibodies. A representative Western blot with monoclonal antibody 249 and 251 is shown in Figure 4 . Both monoclonal antibodies reacted with the 160-231 peptide of murine PrP c , indicating that 249 and 251 bind to the C-terminal region of the PrP molecule. All other monoclonal antibodies from this panel reacted similarly with the C-terminal peptide of PrP. Mouse polyclonal anti-PrP serum (obtained from the mouse used for the original hybridoma fusion) was used as a positive control and this reacted with all three of the truncated PrP peptides.
Detection of cell-surface PrP by FACS
PrP c is a membrane-linked glycoprotein and the copper-bound form of this protein is believed to represent a physiologically relevant form of PrP. It remains to be established if copperloaded PrP c is expressed on the surface of cells that possess this protein. Accordingly, we investigated whether our panel of copper-refolded anti-PrP c monoclonal antibodies was capable of detecting cell-surface expression of PrP c . Figure 5 shows the representative FACS profiles for the reactivity of monoclonal antibody 251 with mouse spleen mononuclear cells isolated from PrP −/− , wild-type and tga20 mice, which express zero, normal and 10-fold levels of PrP c protein respectively. Cells within two electronic gates were assessed : R1, which encompasses small mononuclear cells that probably represent newly divided progenitor mononuclear cells ; and R2, which encompasses mature resting lymphocytes and antigen-presenting cells.
When gate R1 was used to assess the fluorescence intensity, there was a significantly greater level of PrP expression by wildtype and tga20 cells above the background level seen with PrP −/− cells. The level of PrP expression by tga20 cells was approx. 5-fold greater than that seen with wild-type and reflects the increased cellular level of PrP expression by this mouse strain. In contrast, when gate R2 was used to assess PrP expression, there was little, if any, increase in the percentage of cells stained positive for PrP c compared with the background level on PrP −/− cells. The profiles seen with monoclonal 251 were almost identical with those seen when similar cells were reacted with the rabbit polyclonal anti-PrP serum XN, as shown in Figure 5(b) . These data show that monoclonal antibody 251 is capable of reacting with cell-surface PrP c .
Despite the ability of these monoclonal antibodies to recognize PrP, as judged by several techniques including FACS, these antibodies do not appear to react with this protein by immunocytochemistry. The failure of monoclonal antibodies to work effectively by immunocytochemistry is not uncommon and is quite often the case when antibodies are selected using techniques such as ELISA and Western blotting, as occurred with these particular reagents reported in the present study.
Detection of PrP c and PrP Sc
Western-blot analysis was used to characterize the reactivity of this panel of anti-PrP monoclonal antibodies with normal and prion-disease associated forms of PrP. Figure 7 (a) shows that the monoclonal antibodies detected the unglycosylated and monoglycosylated forms of PrP Sc when tested against samples extracted from the prion-infected neuroblastoma cell line N2a58\22L or from scrapie-infected sheep brain material. None of the monoclonal antibodies appeared to react with the diglycosylated form of PrP Sc when compared with the pattern obtained with polyclonal anti-PrP serum such as RB1. Figure  7(b) shows that a similar pattern of reactivity was obtained when PrP Sc from bovine, murine or ovine origin or spleen from scrapieinfected sheep was tested. Importantly, this analysis revealed differences in the Western-blot mobility of PrP Sc from sheep brain homogenates that are thought to be associated with strain specificities. It can be seen that BSE-induced PrP Sc in sheep runs with an apparent lower molecular mass than scrapie-induced PrP Sc in sheep. Figure 7(c) shows that the reactivity of the monoclonal antibodies correlated with the amount of PrP Sc loaded per lane. In addition, the reactivity of the monoclonal antibodies with PrP Sc was decreased after deglycosylation to a single PrP Sc band of approx. 19 kDa depending on its species origin. The monoclonal antibodies showed no reactivity against various tissues from prion-infected animals that were predicted to be negative for PrP Sc , such as spleen from BSE-infected cattle (results not shown). These same samples were also negative for PrP Sc when polyclonal anti-PrP serum RB1 was used for Western blotting (results not shown). The monoclonal antibodies showed no reactivity against proteinase K-treated brain homogenates from uninfected sheep or cattle (results not shown). In addition, no reactivity was seen with PrP Sc samples from these species in the absence of the primary monoclonal antibody (results not shown).
DISCUSSION
The extensive conservation of DNA and protein sequence between different species forms of mammalian PrP c implies a conserved function for this molecule. It has been proposed that PrP c is involved in copper metabolism and a consensus view is that one of the principal sites for metal-ion binding is within the N-terminal octapeptide repeat region of the protein. The octapeptides are comprised of the sequence PHGGGWGQ (where single-letter amino-acid notation has been used) in human PrP and these sequences are extensively conserved between different mammalian forms of this molecule. MS, CD and electron paramagnetic studies, using peptides corresponding to these sequences or full-length PrP, have suggested that each octapeptide binds a single copper(II) ion via a nitrogen from the histidine residue imidazole side chain and deprotonated amide nitrogens from the second and third glycine residues [36, 37] . These structural features of the copper-loaded octapeptide repeat region predict that the side chains of the glutamine residues in each octapeptide repeat unit facilitate intermolecular non-covalent bonding and possible dimerization between PrP molecules [38] . These observations support the view that copper is involved in PrP c function and that metal-ion binding to this molecule modifies its conformational state.
In the present study, we have generated monoclonal antibodies that are specific for PrP by immunization of PrP −/− mice with copper-refolded murine PrP c . When tested by Western-blot analysis, these monoclonal antibodies reacted with similar intensity against recombinant PrP c refolded in the absence or presence of different trace metal elements. However, when tested by ELISA against the same forms of PrP c , when a more native conformation of PrP c would be expected to be present, some of the monoclonal antibodies showed a clear preference for copperrefolded PrP c . In addition, at least one of the monoclonal antibodies showed a preference for manganese-refolded PrP c above that of PrP c refolded in the absence of any metal ion. As each individual monoclonal antibody reacted with these various forms of PrP c in a specific manner, these data support the view that different metal ions are capable of inducing different conformational shapes of the PrP molecule [25] . It is interesting to note that copper and manganese have been implicated in the induction of a conformational change in PrP c associated with increased resistance to proteinase K [24, 28] . In both cases, the proteinase K-resistant fragment resembles, in approximate peptide length, authentic PrP Sc , as the N-terminal region was cleaved during enzymic digestion. Our present results do not reveal which epitope(s) of PrP c are affected by the binding of either copper or manganese. Preliminary regional mapping to localize the epitopes recognized by monoclonal antibody 249 and 251, two antibodies that appear to show a preference for copperrefolded PrP c , revealed their binding within the C-terminal amino acid sequence 160-231. This implies that the binding of copper to either the N-terminal octapeptide repeat region, or possibly some other site within the molecule, may be capable of inducing conformational changes within the C-terminal region of the polypeptide chain or allows greater accessibility of some monoclonal antibodies to their C-terminal epitope. This view is supported by other reports [39, 40] that indicate perturbations in the N-terminal region of PrP influence conformational changes or binding events elsewhere in the molecule. Li et al. [39] have shown that the binding of N-terminus-specific anti-PrP monoclonal antibodies to PrP resulted in the failure of C-terminalspecific antibody to bind the same molecule. This effect appeared to be mediated specifically by the N-terminus portion of the molecule as the binding of monoclonal antibodies to other regions of the protein did not induce the same effect. In addition, the binding of a monoclonal antibody specific to the central portion of PrP showed pH-dependent binding to truncated PrP90-231 [40] . Both of these effects may be attributed to structural changes in the more flexible regions of the PrP molecule, in particular the N-terminal region, which subsequently lead to alterations in epitope exposure in the C-terminal portion of the polypeptide chain. In this regard, it would seem quite likely that subtle changes in the conformational shape of PrP could result from the nature of the metal ion bound to specific sites within the molecule.
We have demonstrated that monoclonal antibodies 249 and 251 are capable of detecting PrP Sc from bovine, ovine and murine origin. In all of these species, both monoclonal antibodies reacted with proteins of approx. 21 and 25 kDa characteristic of the unglycosylated and monoglycosylated forms of PrP Sc [41, 42] . The monoclonal antibodies described also reacted with the corresponding deglycosylated form of PrP Sc from these three species. This latter result, together with the failure to see reactivity with the diglycosylated form of PrP Sc , suggests that the epitope(s) recognized by these particular monoclonal antibodies may be sterically hindered by one or other of the carbohydrate moieties. Monoclonal antibodies with specificity for different glycosylated forms of PrP have been described by Zanusso et al. [43] . These workers have identified a panel of 12 monoclonal antibodies raised to recombinant mouse PrP that could be distinguished by their immunoreactivity with glycosylated and deglycosylated PrP c on immunoblots. The majority of these monoclonal antibodies recognized the C-terminal portion of PrP that contains the two asparagine-linked carbohydrate moieties of PrP. The observations presented in the present study provide further evidence that the epitope(s) recognized by our monoclonal antibodies raised to copper-refolded PrP are located in the Cterminal region of the PrP molecule and may be close to one or other of the two glycosylation sites. Moreover, the apparent molecular masses of these two PrP Sc bands varied according to the species origin of PrP Sc within the infected tissue. Consistent data has been reported that describes differences in the band patterns of PrP Sc following SDS\PAGE and Western blotting, which may be used as a molecular means for the distinction of various prion strains [32, [44] [45] [46] [47] . In the data presented in the current study, Western blot results of natural and experimental isolates of scrapie and BSE were obtained with two of the monoclonal antibodies that show a lower molecular mass of BSE-induced ovine PrP Sc compared with scrapie-derived ovine PrP Sc . These results support data described previously that suggest proteinase K digestion of BSE-derived ovine PrP Sc occurs more distal to the N-terminus compared with that of scrapiederived ovine PrP Sc and results in the appearance of smaller fragments of the BSE associated form of PrP Sc [31, 48] . These molecular characteristics of PrP Sc may be used in conjunction with other properties, such as incubation time and vacuolation patterns [49, 50] , for the characterization of different prion strains.
We have recently shown [51] that brain PrP Sc , which accumulates during the preclinical phase of prion disease, is characterized by a decrease in copper content and an increase in the amount of bound manganese. It has also been reported [52] that PrP Sc from CJD brain homogenates is elevated in manganese and depleted in copper compared with PrP c from normal human brain. These data tentatively suggest that a change in the metal-ion content of PrP may be associated with acquisition of the abnormal form of this molecule. In support of this, it has been shown [25] that conversion of different strains of human CJD PrP Sc can be affected by the variation in their metal-ion content. As the monoclonal antibodies generated in the present study are capable of reacting with recombinant PrP refolded in the absence or presence of metal ions, these data do not allow us to distinguish whether the detectable PrP Sc is loaded with copper, manganese or neither of these metals. Nevertheless, as the absence or presence of divalent metal cations is suggested to influence the cleavage pattern of the PrP Sc molecules [25] , further investigations on the reactivity of the monoclonal antibodies with PrP Sc in the presence of various concentrations of divalent metal cations may reveal further insights into the relationship between proteinase K digestion of PrP Sc and prion strain properties. It will also be relevant to study further the interaction of these monoclonal antibodies with PrP Sc by ELISA, where it may be expected that the PrP molecule is in a more relevant conformational state and the effect of metal-ion binding more clearly shown.
It is a distinct possibility that perturbations in the level of essential trace metal elements are a contributing factor to the formation of PrP Sc during prion disease [51, 53] . We have shown [51] that the preclinical phase of Rocky Mountain Laboratory (' RML ')-induced murine prion disease is associated with an increase in the blood level of manganese. This condition may provide an environment for the exchange of metal ions within PrP and the subsequent formation of disease-specific conformations of this molecule distinct from PrP Sc . Since PrP is expressed on leucocytes [54, 55] , it is further possible that these conformations of the molecule may exist on the surface of such cells during prion disease and therefore represent potential novel diagnostic markers that can readily be identified from blood samples. Recently, it has been shown [56] that altered forms of PrP do reside in the blood of prion-infected individuals as infectivity can be transmitted from BSE-infected sheep to recipient animals by blood transfusion. It will therefore be of interest to determine whether leucocytes from prion-infected individuals do indeed express altered conformations of PrP. We have shown that the anti-PrP monoclonal antibodies generated in the present study are capable of recognizing cell-surface PrP by FACS analysis. These reagents may therefore be used to examine whether alterations occur in expression or conformation of cell-surface PrP on blood cells during the progression of prion disease. In addition, these antibodies also lend themselves to a diagnostic evaluation concerned with the modulation of epitopes within the PrP molecule that may be present in serum during the course of prion disease. We speculate that the panel of monoclonal antibodies generated in the present study may prove useful in elucidating the role of metal ions in the function of PrP.
